Notable Labs Ltd
NASDAQ:NTBL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Notable Labs Ltd
Net Income (Common)
Notable Labs Ltd
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Notable Labs Ltd
NASDAQ:NTBL
|
Net Income (Common)
-$16.7m
|
CAGR 3-Years
15%
|
CAGR 5-Years
2%
|
CAGR 10-Years
N/A
|
|
|
Kamada Ltd
NASDAQ:KMDA
|
Net Income (Common)
$20.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
Enlivex Therapeutics Ltd
NASDAQ:ENLV
|
Net Income (Common)
$1.2B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Urogen Pharma Ltd
NASDAQ:URGN
|
Net Income (Common)
-$153.5m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
N/A
|
|
|
Entera Bio Ltd
NASDAQ:ENTX
|
Net Income (Common)
-$11.4m
|
CAGR 3-Years
4%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
|
Pluri Inc
NASDAQ:PLUR
|
Net Income (Common)
-$26.1m
|
CAGR 3-Years
8%
|
CAGR 5-Years
7%
|
CAGR 10-Years
-2%
|
|
Notable Labs Ltd
Glance View
Notable Labs Ltd is a IL-based company operating in Biotechnology industry. Notable Labs Ltd, formerly Vascular Biogenics Ltd, is an Israel-based clinical-stage biopharmaceutical company committed to developing next-generation, targeted medicines for difficult-to-treat medical conditions. The firm has created a pipeline of therapeutics that address cancer and immune-inflammatory diseases with the goal of significantly improving patient outcomes and overcoming the limitations of approved treatments. The firm's product candidates are built off of two platform technologies: Vascular Targeting System (VTS), a gene-based technology targeting newly formed blood vessels, and Monocyte Targeting Technology (MTT), an antibody-based technology able to specifically inhibit monocyte migration for immune-inflammatory applications.
See Also
What is Notable Labs Ltd's Net Income (Common)?
Net Income (Common)
-16.7m
USD
Based on the financial report for Jun 30, 2024, Notable Labs Ltd's Net Income (Common) amounts to -16.7m USD.
What is Notable Labs Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
2%
Over the last year, the Net Income (Common) growth was -5%. The average annual Net Income (Common) growth rates for Notable Labs Ltd have been 15% over the past three years , 2% over the past five years .
